Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nonmyeloablative allogeneic hematopoietic stem cell transplantation.

F Baron1, Y Beguin

  • 1Department of Medicine, Division of Hematology, University of Liège, 4000 Liège, Belgium.

Journal of Hematotherapy & Stem Cell Research
|May 2, 2002
PubMed
Summary

Nonmyeloablative stem cell transplantation (NMSCT) offers a less toxic approach for hematological malignancies, utilizing the graft-versus-leukemia (GVL) effect. This method shows feasibility and antitumor responses, even in older patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The use of MSCs in steroid-refractory acute GvHD in Europe: a survey from the EBMT cellular therapy & immunobiology working party.

Bone marrow transplantation·2025
Same author

[Acute and chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation].

Revue medicale de Liege·2022
Same author

[Cellular immunotherapy at the University Hospital of Liege : advances, challenges and prospects].

Revue medicale de Liege·2022
Same author

[Editorial. Oncology, at a turning point in its history].

Revue medicale de Liege·2021
Same author

[The Arsène Burny Cancer Institute (ICAB) and its new building for the Integrated Oncology Center (CIO) at the CHU de Liège].

Revue medicale de Liege·2021
Same author

[Allogeneic hematopoietic stem cell transplantation : general principles and recent progress].

Revue medicale de Liege·2021

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Allogeneic hematopoietic stem cell transplantation (HSCT) is effective for hematological malignancies, driven by the graft-versus-leukemia (GVL) effect.
  • Conventional HSCT's toxicity limits its use to younger, healthier patients.
  • Nonmyeloablative stem cell transplantation (NMSCT) protocols were developed to reduce toxicity.

Purpose of the Study:

  • To review the rationale, mechanisms, and efficacy of NMSCT.
  • To present preliminary results from ongoing NMSCT clinical trials.
  • To discuss strategies for enhancing the GVL effect while minimizing graft-versus-host disease (GVHD).

Main Methods:

  • Utilizing immunosuppressive, nonmyeloablative preparative regimens for engraftment.

Related Experiment Videos

  • Employing a two-step approach: initial immunosuppression followed by GVL effect activation.
  • Reviewing data from ongoing clinical trials investigating NMSCT.

    • Main Results:

    • NMSCT is feasible, even in patients over 65 years old, with relatively low transplant-related mortality (TRM).
    • Significant antitumor responses were observed in hematological malignancies and some renal cell carcinoma cases.
    • Preliminary data suggest NMSCT's potential as a less toxic alternative.

    Conclusions:

    • NMSCT is a feasible and potentially effective treatment for selected patients, including older individuals.
    • Further research is needed to demonstrate NMSCT's benefits over alternative treatments.
    • NMSCT should currently be reserved for patients enrolled in clinical trials.